A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis

HJM van Kan; M Spieksma; GJ Groeneveld; Javier Sastre Torano; LH van den Berg; HJ Guchelaar

doi:10.1002/bmc.384

A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis

HJM van Kan^*
, M Spieksma
, GJ Groeneveld
, Javier Sastre Torano
, LH van den Berg
, HJ Guchelaar

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

A specific, accurate and precise high-performance liquid chromatographic assay was developed for the determination of riluzole, a drug used to treat patients with amyotrophic lateral sclerosis. Samples were treated by extraction with dichloromethane followed by reversed-phase chromatography with ultraviolet detection at 260 nm. Preset validation criteria were met from 20 to 2000 ng/mL with a linear response curve. Extraction recovery of riluzole was 65-76%. The accuracy of the method was 102-103%. Intra- and inter-day coefficients of variation were in the ranges 2.8-4.9% and 1.8-9.7%. A detection limit of 5 ng/mL was found. Determination of concentrations in serum and plasma resulted in similar results below 500 ng/mL. At higher values a matrix effect cannot be excluded. This presented method can be used to monitor plasma or serum levels in ALS patients treated with riluzole. Copyright (C) 2004 John Wiley Sons, Ltd.

Original language	English
Pages (from-to)	723-726
Number of pages	4
Journal	Biomedical Chromatography
Volume	18
Issue number	9
DOIs	https://doi.org/10.1002/bmc.384
Publication status	Published - Nov 2004

Keywords

glutamate antagonist
2-amino-6-trifluoromethoxy-betizothiazole
therapeutic drug monitoring
HPLC-UV detection
PHARMACOKINETICS

Access to Document

10.1002/bmc.384

Cite this

@article{51fd44a107e842549aff1aa8dc73745c,

title = "A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis",

abstract = "A specific, accurate and precise high-performance liquid chromatographic assay was developed for the determination of riluzole, a drug used to treat patients with amyotrophic lateral sclerosis. Samples were treated by extraction with dichloromethane followed by reversed-phase chromatography with ultraviolet detection at 260 nm. Preset validation criteria were met from 20 to 2000 ng/mL with a linear response curve. Extraction recovery of riluzole was 65-76\%. The accuracy of the method was 102-103\%. Intra- and inter-day coefficients of variation were in the ranges 2.8-4.9\% and 1.8-9.7\%. A detection limit of 5 ng/mL was found. Determination of concentrations in serum and plasma resulted in similar results below 500 ng/mL. At higher values a matrix effect cannot be excluded. This presented method can be used to monitor plasma or serum levels in ALS patients treated with riluzole. Copyright (C) 2004 John Wiley Sons, Ltd.",

keywords = "glutamate antagonist, 2-amino-6-trifluoromethoxy-betizothiazole, therapeutic drug monitoring, HPLC-UV detection, PHARMACOKINETICS",

author = "\{van Kan\}, HJM and M Spieksma and GJ Groeneveld and \{Sastre Torano\}, Javier and \{van den Berg\}, LH and HJ Guchelaar",

year = "2004",

month = nov,

doi = "10.1002/bmc.384",

language = "English",

volume = "18",

pages = "723--726",

journal = "Biomedical Chromatography",

issn = "0269-3879",

publisher = "John Wiley and Sons Ltd",

number = "9",

}

TY - JOUR

T1 - A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis

AU - van Kan, HJM

AU - Spieksma, M

AU - Groeneveld, GJ

AU - Sastre Torano, Javier

AU - van den Berg, LH

AU - Guchelaar, HJ

PY - 2004/11

Y1 - 2004/11

N2 - A specific, accurate and precise high-performance liquid chromatographic assay was developed for the determination of riluzole, a drug used to treat patients with amyotrophic lateral sclerosis. Samples were treated by extraction with dichloromethane followed by reversed-phase chromatography with ultraviolet detection at 260 nm. Preset validation criteria were met from 20 to 2000 ng/mL with a linear response curve. Extraction recovery of riluzole was 65-76%. The accuracy of the method was 102-103%. Intra- and inter-day coefficients of variation were in the ranges 2.8-4.9% and 1.8-9.7%. A detection limit of 5 ng/mL was found. Determination of concentrations in serum and plasma resulted in similar results below 500 ng/mL. At higher values a matrix effect cannot be excluded. This presented method can be used to monitor plasma or serum levels in ALS patients treated with riluzole. Copyright (C) 2004 John Wiley Sons, Ltd.

AB - A specific, accurate and precise high-performance liquid chromatographic assay was developed for the determination of riluzole, a drug used to treat patients with amyotrophic lateral sclerosis. Samples were treated by extraction with dichloromethane followed by reversed-phase chromatography with ultraviolet detection at 260 nm. Preset validation criteria were met from 20 to 2000 ng/mL with a linear response curve. Extraction recovery of riluzole was 65-76%. The accuracy of the method was 102-103%. Intra- and inter-day coefficients of variation were in the ranges 2.8-4.9% and 1.8-9.7%. A detection limit of 5 ng/mL was found. Determination of concentrations in serum and plasma resulted in similar results below 500 ng/mL. At higher values a matrix effect cannot be excluded. This presented method can be used to monitor plasma or serum levels in ALS patients treated with riluzole. Copyright (C) 2004 John Wiley Sons, Ltd.

KW - glutamate antagonist

KW - 2-amino-6-trifluoromethoxy-betizothiazole

KW - therapeutic drug monitoring

KW - HPLC-UV detection

KW - PHARMACOKINETICS

U2 - 10.1002/bmc.384

DO - 10.1002/bmc.384

M3 - Article

SN - 0269-3879

VL - 18

SP - 723

EP - 726

JO - Biomedical Chromatography

JF - Biomedical Chromatography

IS - 9

ER -

A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis

Abstract

Keywords

Access to Document

Fingerprint

Cite this